BioCryst Pharmaceuticals (NASDAQ:BCRX)
- Dollar Amount of Shares Purchased
- $596,337.56
- Number of Insider Purchases in the Last 180 Days
- 6
- Volume of Shares Purchased
- 103,601
- Who Bought Shares
- Alan G Levin (Director), Anthony Doyle (CFO), Helen M Thackray (Insider), Nancy J Hutson (Director), Steve Aselage (Director) and Steven K Galson (Director)
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Read More
